JP7619587B2 - 腎嚢胞性繊毛病の治療及び／又は予防のための医薬組成物 - Google Patents

腎嚢胞性繊毛病の治療及び／又は予防のための医薬組成物 Download PDF

Info

Publication number
JP7619587B2
JP7619587B2 JP2024553135A JP2024553135A JP7619587B2 JP 7619587 B2 JP7619587 B2 JP 7619587B2 JP 2024553135 A JP2024553135 A JP 2024553135A JP 2024553135 A JP2024553135 A JP 2024553135A JP 7619587 B2 JP7619587 B2 JP 7619587B2
Authority
JP
Japan
Prior art keywords
salts
pharma
pharmaceutical composition
cyst
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024553135A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2024090521A1 (https=
JPWO2024090521A5 (https=
Inventor
健二 長船
伸一 前
妙織 西尾
文彦 八反田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hokkaido University NUC
Kyoto University NUC
Original Assignee
Hokkaido University NUC
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hokkaido University NUC, Kyoto University NUC filed Critical Hokkaido University NUC
Publication of JPWO2024090521A1 publication Critical patent/JPWO2024090521A1/ja
Publication of JPWO2024090521A5 publication Critical patent/JPWO2024090521A5/ja
Application granted granted Critical
Publication of JP7619587B2 publication Critical patent/JP7619587B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024553135A 2022-10-26 2023-10-26 腎嚢胞性繊毛病の治療及び／又は予防のための医薬組成物 Active JP7619587B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022171387 2022-10-26
JP2022171387 2022-10-26
PCT/JP2023/038716 WO2024090521A1 (ja) 2022-10-26 2023-10-26 腎嚢胞性繊毛病の治療及び／又は予防のための医薬組成物

Publications (3)

Publication Number Publication Date
JPWO2024090521A1 JPWO2024090521A1 (https=) 2024-05-02
JPWO2024090521A5 JPWO2024090521A5 (https=) 2024-12-26
JP7619587B2 true JP7619587B2 (ja) 2025-01-22

Family

ID=90830957

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553135A Active JP7619587B2 (ja) 2022-10-26 2023-10-26 腎嚢胞性繊毛病の治療及び／又は予防のための医薬組成物

Country Status (7)

Country Link
US (2) US12514834B2 (https=)
EP (1) EP4574171A4 (https=)
JP (1) JP7619587B2 (https=)
KR (1) KR20250089512A (https=)
CN (1) CN120091831A (https=)
AU (1) AU2023367530A1 (https=)
WO (1) WO2024090521A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7837529B1 (ja) * 2024-11-06 2026-03-31 国立大学法人京都大学 常染色体顕性（優性）多発性嚢胞腎治療用医薬組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021075585A1 (ja) 2019-10-17 2021-04-22 学校法人 杏林学園 腎機能障害の治療剤
WO2022210968A1 (ja) 2021-03-31 2022-10-06 国立大学法人京都大学 嚢胞構造を有する人工集合管オルガノイド

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3633026A4 (en) 2017-05-25 2021-03-10 Kyoto University METHOD FOR INDUCING THE DIFFERENTIATION OF A MESODERMAL INTERMEDIATE CELL TO A KIDNEY PRECURSOR CELL AND METHOD FOR INDUCING THE DIFFERENTIATION OF A PLURIPOTENT STEM CELL FROM A KIDNEY PRECURSOR CELL
US20240010989A1 (en) 2021-01-08 2024-01-11 Kyoto University Medium for culturing and expanding nephron progenitor cells, method for culturing and expanding nephron progenitor cells, and method for producing renal organoids

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021075585A1 (ja) 2019-10-17 2021-04-22 学校法人 杏林学園 腎機能障害の治療剤
WO2022210968A1 (ja) 2021-03-31 2022-10-06 国立大学法人京都大学 嚢胞構造を有する人工集合管オルガノイド

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALTIERI, Paola et al.，"N-(4-hydroxyphenyl)retinamide inhibits cystogenesis by polycystic epithelial cell lines in vitro"，Life Sciences，1999年，Volume 64, Issue 22，Pages PL259-PL265
ISLAM, M. Rafiq et al.，"Retinoic acid-dependent activation of the polycystic kidney disease-1 (PKD1) promoter"，American Journal of Physiology-Renal Physiology，2008年，Volume 295, Issue 6，Pages F1845-F1854
NGUYEN, Que Thanh Thanh et al.，"Synergistic Antiproliferative Effects of All-Trans Retinoic Acid and Paclitaxel on Autosomal Dominant Polycystic Kidney Disease Epithelial Cells"，BioMed Research International，2021年，Volume 2021, Article ID 1242916
PAPADIMITRIOU, Alexandros et al.，"Collecting duct cells show differential retinoic acid responses to acute versus chronic kidney injury stimuli"，Scientific Reports，2020年，volume 10, Article number: 16683

Also Published As

Publication number Publication date
JPWO2024090521A1 (https=) 2024-05-02
EP4574171A4 (en) 2025-12-24
KR20250089512A (ko) 2025-06-18
US12514834B2 (en) 2026-01-06
US20260053763A1 (en) 2026-02-26
CN120091831A (zh) 2025-06-03
EP4574171A1 (en) 2025-06-25
WO2024090521A1 (ja) 2024-05-02
US20250170083A1 (en) 2025-05-29
AU2023367530A1 (en) 2025-03-27

Similar Documents

Publication Publication Date Title
US20250114406A1 (en) Methods and compositions relating to chondrisomes from blood products
Thabet et al. Extracellular vesicles miRNA-21: a potential therapeutic tool in premature ovarian dysfunction
Li et al. Human umbilical cord mesenchymal stem cell-derived exosomes improve ovarian function in natural aging by inhibiting apoptosis
JP5950428B2 (ja) 線維化組織から正常組織を再生するための組成物
US20260053763A1 (en) Pharmaceutical composition for treating and/or preventing renal cystic ciliopathy
JP7163288B2 (ja) 視細胞変性を伴う網膜変性疾患用薬
WO2020205989A1 (en) Small molecule promoting osteoblast differentiation
Yan et al. RNA-binding protein QKI inhibits osteogenic differentiation via suppressing Wnt pathway
US12377092B2 (en) Polycomb inhibitors and uses thereof
US20200188402A1 (en) Compounds and methods for treatment of diamond blackfan anemia
US20120270780A1 (en) Method and composition for modulating erythropoiesis
Lu et al. CPEB2-activated axonal translation of VGLUT2 mRNA promotes glutamatergic transmission and presynaptic plasticity
US20080188449A1 (en) Treatment of Conditions Caused By Calcium Abnormalities
US10668039B2 (en) Methods for treatment of adenoid cystic carcinoma
JP2019089726A (ja) がん遺伝子産物ｙａｐ１／ｔａｚ機能調節剤
JP2014196268A (ja) フルベストラントを含む神経変性疾患の治療又は予防のための医薬組成物
US20240376435A1 (en) Kidney organoid and method for producing same
Higa et al. CD105 maintains the thermogenic program of beige adipocytes by regulating Smad2 signaling
WO2020227385A1 (en) Compounds and methods for treating or preventing fibrosis
CN113827622B (zh) 奇异变形杆菌外膜囊泡在制备预防或治疗骨溶解性疾病药物中的应用
Alotaiq Cavin-1-mediated regulation of suppressor of cytokine signalling 3 (SOCS3) function
Li et al. RNA-binding protein YBX1 promotes Type H vessels dependent bone formation in an m5C-dependent manner
Mehta GATA Factor Mechanisms in Erythrocyte Development
WO2023219119A1 (ja) 生理活性物質を含有する細胞外小胞を生産する方法
Choudhary Modulation of cytokine signaling in optic nerve regeneration in xenopus laevis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241024

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241024

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20241024

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241225

R150 Certificate of patent or registration of utility model

Ref document number: 7619587

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150